Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7381 to 7395 of 7707 results

  1. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued [GID-TA11004]

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued [GID-TA11020]

    Technology appraisal guidance
    Discontinued

  3. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued [GID-TA11244]

    Technology appraisal guidance
    Discontinued

  4. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    Discontinued [GID-TA10958]

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued [GID-TA10583]

    Technology appraisal guidance
    Discontinued

  6. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]

    Discontinued [GID-TA10525]

    Technology appraisal guidance
    Discontinued

  7. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued [GID-TA10185]

    Technology appraisal guidance
    Discontinued

  8. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    Discontinued [GID-TA10502]

    Technology appraisal guidance
    Discontinued

  9. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    Discontinued [GID-TA11255]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued [GID-TA10929]

    Technology appraisal guidance
    Discontinued

  11. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued [GID-TA11204]

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]

    Discontinued [GID-TA10848]

    Technology appraisal guidance
    Discontinued

  13. Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

    Discontinued [GID-TA10861]

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]

    Discontinued [GID-TA10880]

    Technology appraisal guidance
    Discontinued

  15. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer (IPG614)

    This guidance has been updated and replaced by NICE interventional procedures guidance 794.

    Interventional procedures guidance
    Published
    23 May 2018